Get 40% Off
🔥 This hedge fund gained 26.16% in the last month. Get their top stocks with our free stock ideas tool.See stock ideas

Alignment healthcare executive sells over $21k in company stock

Published 03/29/2024, 08:02 PM
ALHC
-

Alignment Healthcare, Inc. (NASDAQ:ALHC) Chief Experience Officer Hakan Kardes recently sold shares in the company, generating over $21,000 in proceeds. The transaction involved the sale of 4,363 shares of common stock at an average price of $4.84 per share.

The shares were sold on March 28, 2024, as indicated by a recent regulatory filing with the Securities and Exchange Commission. It's important to note that the sale was conducted at varying prices ranging from $4.73 to $4.935 per share. This weighted average price reflects the different prices at which the stock was sold during the transaction period.

The sale was not a discretionary trade by Kardes. Instead, it was a necessary action to cover tax withholding obligations associated with the vesting of restricted stock units. Following this transaction, Kardes still holds a significant amount of Alignment Healthcare stock, with 430,444 shares remaining in his possession.

Investors and followers of Alignment Healthcare can request detailed information about the exact number of shares sold at each specific price point within the given range if they wish to gain a clearer understanding of the transaction's structure.

This move by a high-ranking executive within Alignment Healthcare provides insight into the trading activities of the company's insiders and may be of interest to current and potential investors monitoring the stock's performance.

InvestingPro Insights

As Alignment Healthcare, Inc. (NASDAQ:ALHC) navigates through the current market, some notable financial metrics and insights from InvestingPro may shed light on the company's situation. With a market capitalization of approximately $937.33 million and a significant revenue growth in the last twelve months as of Q4 2023, standing at 27.16%, Alignment Healthcare appears to be expanding its market presence. However, despite this growth, the company is facing challenges with profitability. The P/E Ratio as of Q4 2023 stands at -6.39, indicating that the company has not generated a profit over the last year.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Investors considering Alignment Healthcare should be aware of the company's current financial health. One of the InvestingPro Tips points out that Alignment Healthcare holds more cash than debt on its balance sheet, which can be a sign of financial stability. However, another tip reveals that analysts have revised their earnings downwards for the upcoming period, suggesting potential concerns about the company's future earnings potential.

Additionally, the stock has experienced a significant price drop over the last three months, with a 42.39% decrease in total return as of the 90th day of 2024. This is further reflected in the stock's performance over the last month, which saw a 17.33% decline. These trends could be crucial for investors to consider when evaluating the company's stock for their portfolios.

For those looking to delve deeper into Alignment Healthcare's financials and stock performance, InvestingPro offers a wealth of additional tips. In fact, there are 6 more tips available that could provide further insights into the company's valuation, profitability, and stock behavior. To explore these insights and make more informed investment decisions, readers can use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription at InvestingPro.

Alignment Healthcare's next earnings date is set for May 2, 2024, which will be a key event for investors to watch. As the date approaches, staying informed with the latest analysis and data from InvestingPro could be crucial for understanding the company's trajectory and making strategic investment choices.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.